Edgewise Therapeutics Acquired by Servier | Healthcare M&A Deal

Servier has acquired Edgewise Therapeutics, a pharmaceuticals business in Colorado, for $2.65 billion in total potential consideration. Servier acquisitions include sevasemten and the muscular dystrophy portfolio from Edgewise Therapeutics, expanding Servier’s precision therapeutics footprint in healthcare M&A. Edgewise Therapeutics develops muscle disease biopharmaceuticals and is transitioning toward a cardiovascular pipeline with EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for HFpEF. The divestiture acquisition is a strategic acquisition by a strategic buyer, with $1.55 billion upfront cash and up to $1.1 billion in regulatory and commercial milestones, supporting CO acquisitions and funding through key development milestones.